ArticleChemical communications (Cambridge, England)2015
Di-macrocyclic terephthalamide ligands as chelators for the PET radionuclide zirconium-89.
Article in Chemical communications (Cambridge, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer.Molecules (Basel, Switzerland) · 2026Article
- The Evaluation of (1Molecules (Basel, Switzerland) · 2025Article
- Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging.Pharmaceutics · 2024Review
- Bifunctional octadentate pseudopeptides as Zirconium-89 chelators for immuno-PET applications.EJNMMI radiopharmacy and chemistry · 2024Article
- The Race for Hydroxamate-Based Zirconium-89 Chelators.Cancers · 2021Review
- Polyazamacrocycle Ligands FacilitateInorganic chemistry · 2020Article
- A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89.Inorganic chemistry · 2020Article
- Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* forEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89.Biomolecules · 2019Article
- A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevantDalton transactions (Cambridge, England : 2003) · 2018Article
- Recent Advances in Zirconium-89 Chelator Development.Molecules (Basel, Switzerland) · 2018Review
- Review
- Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89.Chemical communications (Cambridge, England) · 2017Article
- Investigation of the complexation ofDalton transactions (Cambridge, England : 2003) · 2017Article
- Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development.Chemical science · 2017Article
- Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89.PloS one · 2017Article
- Article
- Article
- Article
- p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.Bioconjugate chemistry · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The development of bifunctional chelators (BFCs) which can stably chelate zirconium-89 ((89)Zr) while being conjugated to targeting molecules is an area of active research. Herein we report the first octadentate terephthalamide ligands, which are easily radiolabeled with (89)Zr and are highly stable in vitro. They represent a novel class of chelators, which are worthy of further development as BFCs for (89)Zr.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.